Literature DB >> 11727099

A 10-year experience with the use of laparoscopic cholecystectomy for acute cholecystitis: is it safe?

M Suter1, A Meyer.   

Abstract

BACKGROUND: In the era of open surgery, emergency open cholecystectomy has been shown for many reasons to be preferred to delayed surgery for acute cholecystitis. Despite the fact that elective laparoscopic cholecystectomy (LC) has become the gold standard for the treatment of symptomatic gallstone disease, the same procedure remains controversial for the management of acute cholecystitis because it is considered to be associated with more complications and an increased risk of common bile duct injuries than interval LC after resolution of the acute episode. The purpose of this report is to describe our experience with LC for acute cholecystitis during a 10-year period.
METHODS: Patients undergoing laparoscopic surgery have been entered prospectively into a database since 1995. Those who underwent surgery before 1995 were added retrospectively to the same database. Patients were included in this study if they underwent emergency laparoscopic cholecystectomy for suspected acute cholecystitis. The diagnosis was based on clinical, laboratory, and echographic examinations. Analysis was performed to identify risk factors associated with conversion or morbidity.
RESULTS: Of the 1,212 patients subjected to LC between 1990 and 1999, 268 (151 women and 117 men), with a mean age of 53 years, underwent surgery on an emergency basis for suspected acute cholecystitis. Their mean age (p = 0.002) and the proportion of men (p < 0.001) were higher than in the elective group. Delay before admission and surgery varied widely, but 72% of the patients underwent surgery within 48 h of admission. An intraoperative cholangiography, attempted in 218 patients, was successful in 207 (95%). Histologic examination confirmed acute cholecystitis in 82% of the patients. Conversion was necessary in 15.6% of the cases. It occurred more frequently in patients who underwent surgery later than 48 (p = 0.03) or 96 h (p = 0.006) after admission. No other predictor of conversion was found. Overall morbidity was 15.3%, and major morbidity was 4.4%. The only risk factor for morbidity was a bilirubin level greater than 20 mmol/l (p = 0.02). Three partial lesions of the common bile duct occurred. All were recognised and repaired immediately with no adverse effect. There was no difference in the overall rate of biliary complications between the patients operated for acute cholecystitis and those who underwent elective surgery. No reoperation was necessary, and there was no mortality.
CONCLUSIONS: Although LC is safe and effective for acute cholecystitis, its associated morbidity and conversion rate are higher than for elective LC. The conversion rate decreases with experience. When surgery is performed within 2 or maximally 4 days of admission, in experienced hands, LC represents the treatment of choice for acute cholecystitis. Intraoperative cholangiography should be performed in every case because it helps to clarify the anatomy and allows for early diagnosis and repair of bile duct injuries.

Entities:  

Mesh:

Year:  2001        PMID: 11727099     DOI: 10.1007/s004640090098

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  27 in total

1.  Surgical management of acute cholecystitis: results of a 2-year prospective multicenter survey in Belgium.

Authors:  Benoit Navez; Felicia Ungureanu; Martens Michiels; Donald Claeys; Filip Muysoms; Catherine Hubert; Marc Vanderveken; Olivier Detry; Bernard Detroz; Jean Closset; Bart Devos; Marc Kint; Julie Navez; Francis Zech; Jean-François Gigot
Journal:  Surg Endosc       Date:  2012-03-10       Impact factor: 4.584

2.  Original single-incision laparoscopic cholecystectomy for acute inflammation of the gallbladder.

Authors:  Kazunari Sasaki; Goro Watanabe; Masamichi Matsuda; Masaji Hashimoto
Journal:  World J Gastroenterol       Date:  2012-03-07       Impact factor: 5.742

3.  Risk factors for conversion of laparoscopic cholecystectomy to open cholecystectomy.

Authors:  C Simopoulos; S Botaitis; A Polychronidis; G Tripsianis; A J Karayiannakis
Journal:  Surg Endosc       Date:  2005-05-04       Impact factor: 4.584

4.  The national mortality burden and significant factors associated with open and laparoscopic cholecystectomy: 1997-2006.

Authors:  James P Dolan; Brian S Diggs; Brett C Sheppard; John G Hunter
Journal:  J Gastrointest Surg       Date:  2009-09-02       Impact factor: 3.452

5.  The outcome of early laparoscopic surgery to treat acute cholecystitis: a single-center experience.

Authors:  Fatih Ciftci; Ibrahim Abdurrahman; Sadullah Girgin
Journal:  Int J Clin Exp Med       Date:  2015-03-15

6.  Changes in the level of serum liver enzymes after laparoscopic surgery.

Authors:  Min Tan; Feng-Feng Xu; Jun-Shen Peng; Dong-Ming Li; Liu-Hua Chen; Bao-Jun Lv; Zhen-Xian Zhao; Chen Huang; Chao-Xu Zheng
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

7.  Current status of surgical management of acute cholecystitis in the United States.

Authors:  Nicholas Csikesz; Rocco Ricciardi; Jennifer F Tseng; Shimul A Shah
Journal:  World J Surg       Date:  2008-10       Impact factor: 3.352

8.  Delayed laparoscopic subtotal cholecystectomy in acute cholecystitis with severe fibrotic adhesions.

Authors:  Atsushi Horiuchi; Yuji Watanabe; Takashi Doi; Kouichi Sato; Shungo Yukumi; Motohira Yoshida; Yuji Yamamoto; Hiroki Sugishita; Kanji Kawachi
Journal:  Surg Endosc       Date:  2008-04-04       Impact factor: 4.584

9.  Laparoscopic cholecystectomy in empyema of gall bladder: An experience at Liaquat University Hospital, Jamshoro, Pakistan.

Authors:  Arshad Malik; Abdul Aziz Laghari; K Altaf Hussain Talpur; Aisha Memon; Qasim Mallah; Jan Mohammad Memon
Journal:  J Minim Access Surg       Date:  2007-04       Impact factor: 1.407

10.  Laparoscopic cholecystectomy for acute cholecystitis.

Authors:  Angel Iliev Popkharitov
Journal:  Langenbecks Arch Surg       Date:  2008-02-26       Impact factor: 3.445

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.